Categories: News

Promore Pharma’s Annual Report 2021 and AGM related Documents Published

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

STOCKHOLM, SE / ACCESSWIRE / April 26, 2022 / Promore Pharma (STO:PROMO) (FRA:8T0)

The 2021 Annual report of Promore Pharma AB (publ) and all AGM related documents are now available on the Company’s website.

The annual report is available in PDF format on the Company’s website at:
https://www.promorepharma.com/en/section/investors/financial-reports/

Documents related to the AGM, including previously published invitation, is available at:
https://www.promorepharma.com/en/annual-general-meeting-2022/

Printed copies of the annual report can be ordered from Promore Pharma AB, Fogdevreten 2, SE-171 65 Solna, or by e-mail: shareholders@promorepharma.com

About Promore Pharma

Promore Pharma is a biopharmaceutical company that develops pharmaceutical product candidates for bioactive wound care. Today, the company has two drug candidates in late clinical development stages, that are based on endogenous peptides, and thus have a strong safety profile. These two products are intended for treatment of chronic wounds, and prevention of scarring on the skin and other tissues. The company is listed on the Nasdaq First North Growth Market.

For additional information, please contact

Jonas Ekblom, CEO
Phone: [+46] 736 777 540
E-mail: jonas.ekblom@promorepharma.com

Erik Magnusson, CFO
Phone: [+46] 708 565 245
E-mail: erik.magnusson@promorepharma.com

Promore Pharmas Certified Adviser is Erik Penser Bank
Tel: [+46] 8-463 83 00
E-mail: certifiedadviser@penser.se

Link to the report on our site

The full interim report is available at https://www.promorepharma.com/en/section/investors/financial-reports/

Attachments

Promore Pharma AR 2021 ENG FINAL

SOURCE: Promore Pharma

View source version on accesswire.com:
https://www.accesswire.com/698911/Promore-Pharmas-Annual-Report-2021-and-AGM-related-Documents-Published

Staff

Recent Posts

Glassbeam Awarded FedRAMP Authorization for its SAAS analytics solution for connected medical systems by the U.S. Department of Veterans Affairs.

This designation enables Glassbeam to support federal government agency customers increase uptime for all MRI…

42 minutes ago

XtalPi Announces Strategic Acquisition of Liverpool ChiroChem (LCC), Unlocking Unprecedented Power in Chemical Space Exploration

CAMBRIDGE, Mass. and LIVERPOOL, United Kingdom, June 13, 2025 /PRNewswire/ -- XtalPi, a leading life…

42 minutes ago

Mitsubishi Research Institute and Astellas Announce Collaboration to Support Pharma Startups in Japan

Accelerating the Growth of Globally Active Drug-Discovery Startups from Japan TOKYO, June 13, 2025 /PRNewswire/…

42 minutes ago

Maria Ansari, MD, FACC, named to Modern Healthcare’s list of 50 Most Influential Clinical Executives

Co-CEO of The Permanente Federation and leader of multiple Permanente Medical Groups at Kaiser Permanente,…

13 hours ago

Dignify Therapeutics Announces Jeff Welch as Chief Operating Officer

RESEARCH TRIANGLE PARK, N.C., June 12, 2025 /PRNewswire/ -- Dignify Therapeutics (Dignify), a pharmaceutical and medical…

13 hours ago

Transforming Communication in the Workplace and Beyond: Glodean Champion Launches “The Process to LOVE™” – A Revolutionary Communication Framework for Human-Centered Leadership

CHICAGO, June 12, 2025 /PRNewswire/ -- Workplace miscommunication costs businesses an estimated $1.2 trillion annually and…

13 hours ago